Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROLONG Study of first-line pembrolizumab in elderly patients with non-small cell lung cancer
jRCTs061180068Completed
- Start
- Oct 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC). Primary endpoint: Progression-free survival. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs061180068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180068.